NeuroPace has reported positive results from a long-term study of its Next-Gen RNS System to treat refractory epilepsy in the US.

The nine-year study was conducted at 33 epilepsy centres with a total of 256 patients who have not experienced an adequate response to medication.

Results showed a significant reduction in seizures and improved quality of life for patients implanted with the neuromodulation system, the company said.

Next-Gen RNS System is a closed loop brain-responsive neurostimulation device launched by the company in June. Based on a brain-computer interface, the system continuously monitors brain waves and sends imperceptible electrical pulses, even before the occurrence of seizures.

Study principal investigator Dr Dileep Nair said: “This nine-year landmark study is the largest and longest prospective neuromodulation trial in the field of epilepsy.

“These insights have the potential to lead to the treatment of other brain disorders that affect millions of people worldwide.”

“Brain-responsive neurostimulation not only demonstrates compelling long-term seizure reduction for patients, but also provides physicians with ongoing neural recordings that have improved our understanding and treatment of seizures.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

During the study, nearly three out of four patients experienced at least 50% seizure reduction, while one in three achieved a decrease of at least 90%. Across all patients, median seizure reduction was 75% at nine years.

Investigators also observed six months or longer seizure-free periods in 28% of participants, while 18% had seizure-free periods of one year or longer.

In addition, improvements to quality of life in patients were sustained over nine years, without any side-effects associated with chronic stimulation.

NeuroPace chief medical officer Martha Morrell said that completion of the study is set to be followed by application of artificial intelligence to the obtained data set. The technology is expected to optimise therapy settings and improve clinical outcomes.

Morrell added: “The neural data has revealed remarkable discoveries about how the brain functions over months and years; these insights have the potential to lead to the treatment of other brain disorders that affect millions of people worldwide.”